Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement

dc.contributor.author	BLANCO GARCIA, FRANCISCO JAVIER
dc.date.accessioned	2017-06-07T07:36:30Z
dc.date.available	2017-06-07T07:36:30Z
dc.date.issued	2014
dc.identifier.issn	0300-9742
dc.identifier.uri	http://hdl.handle.net/20.500.11940/8478
dc.language.iso	eng
dc.title	Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement
dc.type	Publicación de congreso
dc.authorsophos	Edwards, C.
dc.authorsophos	Blanco, F.
dc.authorsophos	Crowley, J.
dc.authorsophos	Hu, C. C.
dc.authorsophos	Stevens, R.
dc.authorsophos	Birbara, C.
dc.identifier.sophos	15318
dc.issue.number	s
dc.journal.title	SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Reumatoloxía
dc.page.initial	67
dc.page.final	68
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	43

Files in this item

Files	Size	Format	View
There are no files associated with this item.